Blog
RSS FeedPosted by Michael Wonder on 09 Sep 2021
Controversy over using quality adjusted life years in cost effectiveness analyses: a systematic literature review
8 September 2021 - Researchers and policy makers in the US are exploring the implementation of health technology assessment and value ...
Posted by Michael Wonder on 22 Aug 2021
Accelerated approval - an unexpected pathway to value-based pricing?
18 August 2021 - Accelerated approval is an important regulatory pathway that provides early access to treatments for patients with serious ...
Posted by Michael Wonder on 17 Jul 2021
Aduhelm pros and cons debated at ICER meeting
16 July 2021 - Biogen officials defended the company's Alzheimer's drug and criticised ICER's cost effectiveness report today at a meeting ...
Posted by Michael Wonder on 21 Jun 2021
Are drugs priced in accordance with value? A comparison of value based and net prices using Institute for Clinical and Economic Review reports
19 June 2021 - The Institute for Clinical and Economic Review is an independent organisation that reviews drugs and devices with ...
Posted by Michael Wonder on 07 May 2021
Rather than turning its back on the QALY, pharma should collaborate on efforts to improve it
7 May 2021 - A key element in the long-simmering debate on reining in drug prices in the United States ...
Posted by Michael Wonder on 22 Apr 2021
The thorny issue of value alignment: how development-focused health technology assessment can help find win–win situations for patients and health care systems and commercial investors
20 April 2021 - We agree that there is always likely to be some tension between commercial interests and maximising societal ...
Posted by Michael Wonder on 27 Jan 2021
On the role of cost effectiveness thresholds in health care priority setting
25 January 2021 - In the past few years, empirical estimates of the marginal cost at which health care produces a ...
Posted by Michael Wonder on 04 Dec 2020
ICER opens nominations for new members of its voting panels
2 December 2020 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...
Posted by Michael Wonder on 03 Dec 2020
The real worth of cancer drugs
1 December 2020 - In November, 2020, we witnessed one of the most awaited elections in recent times—the USA elected Joe ...
Posted by Michael Wonder on 29 Nov 2020
Will COVID-19 vaccines be cost effective—and does it matter?
26 November 2020 - The costs of other pandemic measures mean that covid-19 vaccines will probably turn out to be ...
Posted by Michael Wonder on 19 Nov 2020
Consideration of value-based pricing for treatments and vaccines is important, even in the COVID-19 pandemic
19 November 2020 - Prices send signals about consumer preferences and thus stimulate producers to make more of what people want. ...
Posted by Michael Wonder on 07 Nov 2020
A health opportunity cost threshold for cost effectiveness analysis in the United State
3 November 2020 - Cost effectiveness analysis is an important tool for informing treatment coverage and pricing decisions, yet no consensus ...
Posted by Michael Wonder on 23 Oct 2020
Efficiency ratio and rocketing drug prices: old concerns and new possibilities
23 October 2020 - One of the most significant phenomena in the recent years concerning the pharmaceutical industry and, at ...
Posted by Michael Wonder on 06 Oct 2020
FDA announces all time low rates for FY2021 priority review vouchers
5 October 2020 - The US FDA has announced historic low rates for the fiscal year 2021 fees to use ...
Posted by Michael Wonder on 05 Oct 2020
De-adopting low value care: evidence, eminence and economics
2 October 2020 - An often cited shortcoming of the US health care system is the slow pace with which ...